Liver Enzymes as Biomarkers for Hepatotoxicity of Statins in Patients with Dyslipidemia

Velickova, Nevenka and Nateva, Marina and Stojanovska, Slagana (2019) Liver Enzymes as Biomarkers for Hepatotoxicity of Statins in Patients with Dyslipidemia. CMBEBIH 2019 Proceedings of the International Conference on Medical and Biological Engineering, 73. pp. 611-615. ISSN 978-3-030-17971-7 (online)

[thumbnail of Velickova_Chapter_Author_first page_Springer nature.pdf]
Velickova_Chapter_Author_first page_Springer nature.pdf

Download (289kB) | Preview


Various chemical agents or pharmaceuticals as drugs
administered into the body in increased concentrations for
a long time may have hepatotoxic or carcinogenic effect.
In human biomonitoring are used different biomarkers,
which can confirm the presence of various chemical
agents in the body and their effects on cells or molecules.
The aim of the study is to biomonitoring of the
hepatotoxic effects of statins (atorvastatin and rosuvastatin)
as a chemical agents or drugs in therapy of patients
with dyslipidemia, using biochemical biomarkers as liver
enzymes. Materials and methods: Follow-up laboratory
tests (AST, ALT, GGT, ALP, cholesterol, and triglycerides)
were evaluated with biochemical analyzer Cobas
Integra 400 Plus, after 6 months of treatment with statins.
The study included 28 subjects, aged 28–84 years (the
mean 63.7), 15 women and 13 men, mainly patients with
confirm dyslipidemia. Results: The observation of total
serum transferases confirmed that 20 of the subjects
(71.42%) have a normal serum transferases (AST and
ALT) but 8 of the subjects (28.58%) (Groups 1 and 2)
have a abnormal level of serum transferases. Subjects in
Group 1 (5 subjects with atorvastatin therapy) have an
abnormal level of serum transferases (AST and ALT), the
mean value of AST was 43.6 U/L and for ALT 73.6 U/L.
Subject in Group 2 (3 subjects with rosuvastatin therapy)
has >10 times more of the level of AST and ALT (the
mean value of AST was 580.3 U/L, and ALT 1802.3
U/L). In the Group 2 we reported older patients (with theages after 60) with long time therapy with rosuvastatin
(more than 6 months) who demonstrated significant
elevation of ALT according with other chronical diseases
as a cardiovascular diseases, diabetes mellitus type 2,
acute pancreatitis and in alcohol abusers. Conclusions:
We want to emphasize the importance of biomonitoring
of liver enzymes as biomarkers which associates hepatotoxicity. Statins therapy (on patients with dyslipidemia) combined with other metabolic drugs and inhibitors, might increase the risk of liver injury. Individual differences, such as sex, age, sensitivity and immune ability, affect the degree of hepatotoxicity of various drugs (in our study statins) as a chemical agents present in the body.

Item Type: Article
Subjects: Medical and Health Sciences > Basic medicine
Divisions: Faculty of Medical Science
Depositing User: Nevenka Velickova
Date Deposited: 14 Aug 2019 07:49
Last Modified: 14 Aug 2019 07:49

Actions (login required)

View Item View Item